- Home
- VHI vs MREO Comparison
VHI vs MREO Comparison
Compare VHI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VHI
- MREO
- Stock Information
- Founded
- VHI 1932
- MREO 2015
- Country
- VHI United States
- MREO United Kingdom
- Employees
- VHI N/A
- MREO N/A
- Industry
- VHI Major Chemicals
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- VHI Industrials
- MREO Health Care
- Exchange
- VHI Nasdaq
- MREO Nasdaq
- Market Cap
- VHI 509.6M
- MREO 438.8M
- IPO Year
- VHI N/A
- MREO N/A
- Fundamental
- Price
- VHI $15.44
- MREO $1.53
- Analyst Decision
- VHI Sell
- MREO Strong Buy
- Analyst Count
- VHI 1
- MREO 5
- Target Price
- VHI $12.00
- MREO $7.20
- AVG Volume (30 Days)
- VHI 9.8K
- MREO 2.1M
- Earning Date
- VHI 08-07-2025
- MREO 08-19-2025
- Dividend Yield
- VHI 2.08%
- MREO N/A
- EPS Growth
- VHI 269.89
- MREO N/A
- EPS
- VHI 3.44
- MREO N/A
- Revenue
- VHI $2,109,500,000.00
- MREO N/A
- Revenue This Year
- VHI $22.20
- MREO N/A
- Revenue Next Year
- VHI $7.66
- MREO $38.38
- P/E Ratio
- VHI $4.44
- MREO N/A
- Revenue Growth
- VHI 4.01
- MREO N/A
- 52 Week Low
- VHI $14.10
- MREO $1.53
- 52 Week High
- VHI $41.75
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- VHI 36.01
- MREO 28.79
- Support Level
- VHI $15.28
- MREO $1.71
- Resistance Level
- VHI $15.93
- MREO $1.65
- Average True Range (ATR)
- VHI 0.51
- MREO 0.08
- MACD
- VHI -0.24
- MREO 0.01
- Stochastic Oscillator
- VHI 9.52
- MREO 2.70
About VHI Valhi Inc.
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).